Company Statement: Par Pharmaceutical completes acquisition of Anchen
MLex Summary: Par Pharmaceutical has completed its $410 million acquisition of fellow generic-drug manufacturer Anchen Pharmaceuticals. Both companies specialize in a more specialized subset of generic drugs, including extended release products and...To view the full article, register now.
Already a subscriber? Click here to view full article